REFRACTORY INTERDIGITATING DENDRITIC CELL SARCOMA

Clinical trials for REFRACTORY INTERDIGITATING DENDRITIC CELL SARCOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY INTERDIGITATING DENDRITIC CELL SARCOMA trials appear

Sign up with your email to follow new studies for REFRACTORY INTERDIGITATING DENDRITIC CELL SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill aims to turn immune system against tough blood cancers

Disease control Recruiting now

This early-stage study is testing a new oral medication called Q702 for patients with advanced blood cancers and rare immune cell disorders that have not responded to standard treatments. The main goals are to find the safest dose and see what side effects occur. Researchers hope…

Matched conditions: REFRACTORY INTERDIGITATING DENDRITIC CELL SARCOMA

Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control

Last updated Mar 12, 2026 13:52 UTC

REFRACTORY INTERDIGITATING DENDRITIC CELL SARCOMA

Get alerted when new REFRACTORY INTERDIGITATING DENDRITIC CELL SARCOMA trials appear

New pill aims to turn immune system against tough blood cancers